Eric Pauwels - 08 Jan 2026 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
CHIEF BUSINESS OFFICER
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Issuer symbol
PTCT
Transactions as of
08 Jan 2026
Net transactions value
-$565,946
Form type
4
Filing time
12 Jan 2026, 17:20:13 UTC
Previous filing
08 Jan 2026
Next filing
20 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Pauwels Eric CHIEF BUSINESS OFFICER C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN /s/ Avraham S. Adler, Attorney-in-Fact 12 Jan 2026 0001323212

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Sale $195,712 -2,561 -2.9% $76.42 84,928 08 Jan 2026 Direct F1, F2
transaction PTCT Common Stock Sale $45,187 -587 -0.69% $76.98 84,341 08 Jan 2026 Direct F1, F3
transaction PTCT Common Stock Sale $111,158 -1,454 -1.7% $76.45 82,887 08 Jan 2026 Direct F4
transaction PTCT Common Stock Sale $133,300 -1,722 -2.1% $77.41 81,165 09 Jan 2026 Direct F1, F5
transaction PTCT Common Stock Sale $80,589 -1,024 -1.3% $78.70 80,141 12 Jan 2026 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2025.
F2 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.89 to $76.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.91 to $77.13 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs.
F5 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.10 to $77.77 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F6 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.16 to $79.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.